Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus?
Yükleniyor...
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Medical University of Plovdiv
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Introduction: Sclerostin is a glycoprotein known as a negative regulator of bone formation, predominantly expressed by mature
osteocytes. There is no causative evidence information on the role of sclerostin in the pathogenesis of type 2 diabetes mellitus (T2DM)
in humans.
Aim: This study aimed to investigate the relationship between serum sclerostin levels and oxidative status and biochemical parameters
in T2DM patients and healthy people.
Materials and methods: This cross-sectional study, conducted in a clinical trial center, included 45 subjects with T2DM and 45 subjects as controls.
Results: Serum sclerostin, total oxidative status (TOS), albumin, and ferritin levels were significantly higher in T2DM patients than
in the control group (p<0.05). Total antioxidant status (TAS) was significantly higher in the control group (p<0.05). There was a weak
positive correlation between sclerostin and TOS (r=0.23, p=0.03) and a weak negative correlation between sclerostin and TAS (r=−0.28,
p=0.03).
Conclusions: We have demonstrated that serum sclerostin levels increase in patients with T2DM and that the increased sclerostin levels
are associated with oxidative stress.
Açıklama
Anahtar Kelimeler
Sclerostin, TAS, TOS, Type 2 diabetes mellitus
Kaynak
Folia Medica
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
65
Sayı
1
Künye
Sabancılar, İ., Unsal, V., Demir, F., Toprak, G. ve Pekkolay, Z. (2023). Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus?. Folia Medica, 65(1), 46-52.
